Institute of Health Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.
Department of Clinical Microbiology, Clinical Hospital No. 2, 35-301 Rzeszow, Poland.
Int J Mol Sci. 2024 Jun 25;25(13):6935. doi: 10.3390/ijms25136935.
Crohn's disease (CD) progresses with periods of remission and exacerbations. During exacerbations, chronic inflammation leads to tissue destruction. As a result, intestinal fibrosis may develop in response to the ongoing inflammatory process. Fibrosis in CD should be considered the result of the response of the intestinal wall (over) to the presence of inflammation in the deep structures of the intestinal wall. In the absence of ideal noninvasive methods, endoscopic evaluation in combination with biopsy, histopathological analysis, stool analysis, and blood analysis remains the gold standard for assessing both inflammation and fibrosis in CD. On the contrary, the ability to identify markers of intestinal fibrosis would help to develop new diagnostic and therapeutic methods to detect early stages of fibrosis. It is speculated that miRNAs may, in the future, become biomarkers for early noninvasive diagnosis in the treatment of intestinal fibrosis. The purpose of this review is to summarise existing diagnostic methods for Crohn's disease and present recent scientific reports on molecular testing.
克罗恩病(CD)呈缓解与加重交替的病程,在加重期,慢性炎症导致组织破坏,在持续的炎症反应下,肠道可能发生纤维化。因此,CD 的纤维化应被视为肠道壁(过度)对肠道壁深层结构炎症存在的反应结果。在缺乏理想的非侵入性方法的情况下,内镜评估结合活检、组织病理学分析、粪便分析和血液分析仍然是评估 CD 炎症和纤维化的金标准。相反,能够识别肠道纤维化标志物将有助于开发新的诊断和治疗方法以检测纤维化的早期阶段。据推测,miRNA 将来可能成为治疗肠道纤维化的早期无创诊断的生物标志物。本综述的目的是总结现有的 CD 诊断方法,并介绍关于分子检测的最新科学报告。